Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052882 · ClinicalTrials.gov registry record · Phase 2
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02052882: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02052882 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02052882, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is to determine if using weekly romiplostim injections will improve the patient's platelet count more effectively than simply waiting for the platelets to improve on its own, and if romiplostim will also allow the patient to receive at least 2 further cycles of chemotherapy without thrombocytopenia.
Interventions
- BIOLOGICAL romiplostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-01-30 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052882
The ClinicalTrials.gov registry entry for NCT02052882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which romiplostim is the first listed.
NCT02052882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052882 about?
NCT02052882 is a clinical study titled "Study of Romiplostim for Chemotherapy Induced Thrombocytopenia". This study is to determine if using weekly romiplostim injections will improve the patient's platelet count more effectively than simply waiting for the platelets to improve on its own, and if romiplostim will also allow the patient to receive at least 2 further cycles of chemotherapy without thromb...
What is the current status of trial NCT02052882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-01-30. Estimated completion is 2023-11-13.
What interventions are being tested in trial NCT02052882?
The interventions under investigation include: romiplostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT02052882?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.